1. Home
  2. KALV vs VSTS Comparison

KALV vs VSTS Comparison

Compare KALV & VSTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • VSTS
  • Stock Information
  • Founded
  • KALV N/A
  • VSTS 1936
  • Country
  • KALV United States
  • VSTS United States
  • Employees
  • KALV N/A
  • VSTS N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • VSTS
  • Sector
  • KALV Health Care
  • VSTS
  • Exchange
  • KALV Nasdaq
  • VSTS Nasdaq
  • Market Cap
  • KALV 796.4M
  • VSTS 819.7M
  • IPO Year
  • KALV N/A
  • VSTS N/A
  • Fundamental
  • Price
  • KALV $13.50
  • VSTS $4.11
  • Analyst Decision
  • KALV Strong Buy
  • VSTS Sell
  • Analyst Count
  • KALV 8
  • VSTS 4
  • Target Price
  • KALV $26.43
  • VSTS $9.13
  • AVG Volume (30 Days)
  • KALV 1.0M
  • VSTS 1.5M
  • Earning Date
  • KALV 09-11-2025
  • VSTS 08-05-2025
  • Dividend Yield
  • KALV N/A
  • VSTS 1.71%
  • EPS Growth
  • KALV N/A
  • VSTS N/A
  • EPS
  • KALV N/A
  • VSTS N/A
  • Revenue
  • KALV $1,426,000.00
  • VSTS $2,707,109,000.00
  • Revenue This Year
  • KALV N/A
  • VSTS N/A
  • Revenue Next Year
  • KALV $213.43
  • VSTS $0.25
  • P/E Ratio
  • KALV N/A
  • VSTS N/A
  • Revenue Growth
  • KALV N/A
  • VSTS N/A
  • 52 Week Low
  • KALV $7.30
  • VSTS $3.98
  • 52 Week High
  • KALV $17.28
  • VSTS $17.83
  • Technical
  • Relative Strength Index (RSI)
  • KALV 44.26
  • VSTS 48.68
  • Support Level
  • KALV $13.26
  • VSTS N/A
  • Resistance Level
  • KALV $17.28
  • VSTS $4.37
  • Average True Range (ATR)
  • KALV 1.03
  • VSTS 0.20
  • MACD
  • KALV -0.10
  • VSTS -0.14
  • Stochastic Oscillator
  • KALV 9.13
  • VSTS 85.80

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

Share on Social Networks: